Scenarios that move MEDP
Medpace Holdings, Inc. - Common Stock
Scenarios that move MEDP: 13 analyses, 10 positive, 3 negative.
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -8 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +26 · confidence low · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +12 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▲ · impact +4 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +11 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +12 · confidence low · horizon quarters
- · Beta Bionics stock plunges 37% after safety issues emerge — ▲ · impact +6 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +25 · confidence low · horizon quarters
- · Satellos wins FDA IND clearance for Forazapadin in FSHD — ▲ · impact +45 · confidence low · horizon immediate
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▲ · impact +12 · confidence low · horizon quarters
- · Xenon files epilepsy NDA as depression study setback weighs — ▼ · impact -8 · confidence low · horizon weeks
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -12 · confidence low · horizon quarters
- · Definium reports second Phase III success in anxiety program — ▲ · impact +15 · confidence low · horizon quarters